相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。B7-H4 facilitates proliferation of esophageal squamous cell carcinoma cells through promoting interleukin-6/signal transducer and activator of transcription 3 pathway activation
Xinran Chen et al.
CANCER SCIENCE (2016)
Preoperative Serum Interleukin-6 Is a Potential Prognostic Factor for Colorectal Cancer, including Stage II Patients
Kazuyoshi Shiga et al.
GASTROENTEROLOGY RESEARCH AND PRACTICE (2016)
Upregulated interleukin-6 expression contributes to erlotinib resistance in head and neck squamous cell carcinoma
Aditya Stanam et al.
MOLECULAR ONCOLOGY (2015)
Cancer-Associated Fibroblasts: Their Characteristics and Their Roles in Tumor Growth
Kazuyoshi Shiga et al.
CANCERS (2015)
Interleukin-6 released by colon cancer-associated fibroblasts is critical for tumour angiogenesis: anti-interleukin-6 receptor antibody suppressed angiogenesis and inhibited tumour-stroma interaction
T. Nagasaki et al.
BRITISH JOURNAL OF CANCER (2014)
Interleukin-6: An angiogenic target in solid tumours
Kathryn Middleton et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2014)
Proangiogenic tumor proteins as potential predictive or prognostic biomarkers for bevacizumab therapy in metastatic colorectal cancer
Maressa A. Bruhn et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
Aqueous Interleukin-6 Levels Are Superior to Vascular Endothelial Growth Factor in Predicting Therapeutic Response to Bevacizumab in Age-Related Macular Degeneration
Kakarla V. Chalam et al.
JOURNAL OF OPHTHALMOLOGY (2014)
Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy
J. M. Juergensmeier et al.
BRITISH JOURNAL OF CANCER (2013)
Predictive Impact of Circulating Vascular Endothelial Growth Factor in Four Phase III Trials Evaluating Bevacizumab
Priti S. Hegde et al.
CLINICAL CANCER RESEARCH (2013)
Monoclonal antibodies in lung cancer
Yujiong Wang et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2013)
Changes in Circulating Pro-Angiogenic Cytokines, other than VEGF, before Progression to Sunitinib Therapy in Advanced Renal Cell Carcinoma Patients
Camillo Porta et al.
ONCOLOGY (2013)
Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study
Atsushi Ohtsu et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Signaling Pathways Governing Tumor Angiogenesis
Toshiharu Sakurai et al.
ONCOLOGY (2011)
Predictive and Prognostic Biomarkers for Targeted Therapy in Metastatic Colorectal Cancer
Uzma Asghar et al.
CLINICAL COLORECTAL CANCER (2010)
Phase II Trial of Bevacizumab and Everolimus in Patients With Advanced Renal Cell Carcinoma
John D. Hainsworth et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Combined targeting of interleukin-6 and vascular endothelial growth factor potently inhibits glioma growth and invasiveness
Ahlame Saidi et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Efficacy, Safety, and Biomarkers of Neoadjuvant Bevacizumab, Radiation Therapy, and Fluorouracil in Rectal Cancer: A Multidisciplinary Phase II Study
Christopher G. Willett et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Antitumor effect of the angiogenesis inhibitor bevacizumab is dependent on susceptibility of tumors to hypoxia-induced apoptosis
Muthu Selvakumaran et al.
BIOCHEMICAL PHARMACOLOGY (2008)
Regulation of liver regeneration and hepatocarcinogenesis by suppressor of cytokine signaling 3
Kimberly J. Riehle et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2008)
Delta-like 4 notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo
Ji-Liang Li et al.
CANCER RESEARCH (2007)
Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis
GL Niu et al.
ONCOGENE (2002)
分享论文
